Document/Exhibit Description Pages Size
1: 8-K Current Report on Form 8-K 4 13K
3: EX-99 Ex. 99.2 - Press Release of September 25, 1998 2± 11K
2: EX-99 Exhibit 99.1 - Press Release of September 28, 1998 2± 12K
=============================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 25, 1998
SCHEIN PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
1-14019 11-2726505
------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
100 Campus Drive
Florham Park, New Jersey 07932
(Address of principal executive offices)
(973) 593-5500
--------------------------------------------------
(Registrant's telephone number, including area code)
=============================================================
Inapplicable
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS.
On September 28, 1998, Schein Pharmaceutical, Inc. ("Schein") announced
that it will reduce its workforce by approximately 350 employees at its Phoenix,
Arizona facilities. The workforce reduction results from the Food and Drug
Administration ("FDA") action of September 10, 1998 that had the effect of
halting the manufacturing and distribution of all products from Schein's
subsidiary Steris Laboratories, Inc. in Phoenix. Schein is continuing to work
with the FDA to reach a consent agreement.
On September 25, 1998, Schein announced that it had been served with
two class action securities lawsuits and is aware of additional suits since the
FDA action of September 10, 1998.
A copy of each press release referred to above is attached to this Form
8-K as an Exhibit and is incorporated herein by reference.
Certain of the matters discussed in this Current Report on Form 8-K and
in the press releases attached as exhibits hereto contain statements concerning
future events or results. These "forward looking" statements involve certain
significant risks and uncertainties, and actual results may differ materially
from the forward-looking statements. Some important factors which may cause
results to differ include: the difficulty of predicting FDA approvals, the
uncertainty of the actions and responses of the FDA, the uncertainty of
acceptance and demand for the Company's new products, the impact of competitive
products and pricing, the availability of raw materials, uncertainties
associated with litigation and regulatory matters, and fluctuations in operating
results. Other important factors that may cause actual results to differ
materially from the forward looking statements are discussed in the "Risk
Factors" and "Management's Discussion & Analysis of Financial Condition and
Results of Operations" sections of the Company's prospectus dated April 8, 1998,
which is on file with the Securities and Exchange Commission as part of the
Company's Registration Statement on Form S-1. Readers are urged to read the
prospectus carefully to better understand these factors. The Company does not
undertake to publicly update or revise any of its forward looking statements
even if experience or future changes show that the indicated results or events
will not be realized.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(C) EXHIBITS
99.1 Press Release dated September 28, 1998.
99.2 Press Release dated September 25, 1998.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
SCHEIN PHARMACEUTICAL, INC.
DARIUSH ASHRAFI
Dated: September 30, 1998 By:_________________________________
Dariush Ashrafi
Executive Vice President and
Chief Financial Officer
INDEX TO EXHIBITS
Exhibit No. Description
-------------- ------------
99.1 Press Release dated September 28, 1998
99.2 Press Release dated September 25, 1998.
Dates Referenced Herein and Documents Incorporated by Reference
↑Top
Filing Submission 0000927796-98-000257 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Thu., Apr. 25, 7:39:21.1am ET